Solid Tumor Clinical Trial
Official title:
A Multicenter, Open Label, Uncontrolled Phase I Trial to Compare Safety, Tolerability and Immunogenicity of Vx-006 Vaccine at 0.5mg, 1mg, 5mg and 10mg Doses in Human Leukocyte Antigen-A02 (HLA-A02) Positive Patients With Solid Tumours
NCT number | NCT02289196 |
Other study ID # | Vx-006-101 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | March 2014 |
Est. completion date | May 2017 |
Verified date | June 2019 |
Source | Vaxon Biotech |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with histologically proven malignancy with documented disease control (objective
response or stable disease) or Not Evaluable Disease (NED) expectancy > 6 months; only
HLA-A*02 positive patients.
The primary objective of the trial is to compare safety and tolerability of four different
doses of Vx-006. The secondary objective is to compare immunogenicity of four different doses
of the Vx-006.
Status | Completed |
Enrollment | 23 |
Est. completion date | May 2017 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or female > or = 18 years of age; 2. Histologically proven malignancy; 3. Documented HLA-A*02 positivity, as determined by a central laboratory; 4. Disease control (Complete Response (CR), Partial Response (PR), or Stable Disease (SD)) according to Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria or NED in the case of patients who received adjuvant chemotherapy 5. Patient with disease control or NED expectancy > or = 6 months according to investigator opinion; 6. ECOG performance status 0, 1; 7. Patients must have adequate renal and hepatic function as assessed by standard laboratory criteria; 8. Patients must have adequate haematological function: - Platelet count > or = 100 x 109/L; - White Blood Cell (WBC) count > or = 2.5 x 109/L; - Haemoglobin > or = 90g /L; 9. Female patients must be of non-child-bearing potential (i.e., women with functioning ovaries who have a documented tubal ligation or hysterectomy, ovariectomy or women who are post-menopausal). Women of child-bearing potential must have a negative urine pregnancy test at baseline and agree to practice adequate contraception for 30 days prior to administration of investigational product, throughout the study treatment period and 30 days after completion of injections; 10. In the investigator's opinion, the patient is capable and willing to comply with the requirements of the study; 11. Willing and able to sign a written informed consent. Exclusion Criteria: 1. Prior treatment with cancer vaccines; 2. Treatment with immunotherapy (e.g., interferons, interleukins, Tumor Necrosis Factor (TNF), or biological response modifiers, such as Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) etc) within four weeks prior to the first vaccination; 3. Treatment with immunosuppressive agents (including corticosteroids) within 2 weeks prior to the first vaccination; 4. Treatment with any investigational drugs, within 4 weeks prior to the first vaccination; 5. Autoimmune or immunodeficiency disease that in the opinion of the investigator may compromise the safety of the patient in the study; 6. Any pre-existing medical condition requiring concomitant systemic corticosteroid or immunosuppressive therapy. The use of inhaled corticosteroids for Chronic Obstructive Pulmonary Disease (COPD) or topical steroids is allowed; 7. Known hepatitis B and/or C infection documented in patient files, testing not required; 8. Known HIV-positivity, testing not required; 9. Clinically significant hepatic dysfunction (Alanine amino transferase (ALT)>2.5 times normal upper limits [ULN], Aspartate Amino Transferase (AST)>2.5 times Upper Limit of Normal (ULN), bilirubin>1.5 times ULN); 10. Clinically significant renal dysfunction (serum creatinine>1.5 time ULN); 11. Uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease with unstable angina or myocardial infarction within 6 months before enrolment) or uncontrolled ventricular arrhythmias at the time of enrolment in the study (atrial fibrillation or flutter is acceptable); 12. Splenectomy or splenic irradiation; 13. Any infectious condition that, in the opinion of the investigator, could compromise the patient's ability to develop an immune response; 14. Pregnant or lactating females (female patients of child-bearing potential will undertake pregnancy testing at screening and during study completion/withdrawal visits); 15. Alcohol or drug dependence; 16. Requirement of concurrent treatment with prohibited medication (investigational product, other anti-cancer treatments including chemotherapy, non-palliative radiotherapy, biological agents and immunomodulating agents, systemic immunosuppressive agents, including systemic corticosteroids); 17. The investigator considers the patient unfit for the study as a result of the medical interview, physical examination, or screening investigations. |
Country | Name | City | State |
---|---|---|---|
Greece | 251 General Airforce Hospital | Athens | |
Greece | Iaso General Hospital | Athens | |
Greece | University General Hospital of Heraklion | Heraklion, Crete |
Lead Sponsor | Collaborator |
---|---|
Vaxon Biotech |
Greece,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse event number by treatment group as a measure of safety and tolerability | The following parameters of safety and tolerability will be assessed: Physical examination and vital signs (blood pressure, pulse rate, body temperature, weight, height (only at baseline), Electrocardiogram, Adverse event evaluation, Eastern Cooperative Oncology Group (ECOG) performance status, Clinical laboratory evaluation: haematology and clinical chemistry Collection of concomitant medication |
18 Weeks | |
Secondary | Immune response evaluation by treatment group as a measure of efficacy | 18 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |